New hope for bladder cancer patients who Can't take chemo?

NCT ID NCT03459846

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the drug combo or a placebo. The study aims to see if the combination slows cancer growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and olaparib
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced bladder cancer patients who cannot tolerate standard chemotherapy.
What could go wrong: This is a Phase 2 trial with only 154 participants, so results are preliminary. The combination may not improve survival and could cause side effects like fatigue, nausea, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE STAGE IV UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY BLADDER NEOPLASMS

Contacts and locations

Locations

Research Site

Birmingham, Alabama, 35294, United States
Research Site

Goodyear, Arizona, 85338, United States
Research Site

Fort Myers, Florida, 33901, United States
Research Site

St. Petersburg, Florida, 33705, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Louisville, Kentucky, 40202, United States
Research Site

New Hyde Park, New York, 11042, United States
Research Site

New York, New York, 10065, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Philadelphia, Pennsylvania, 19124, United States
Research Site

Nashville, Tennessee, 37232, United States
Research Site

Tacoma, Washington, 98405, United States
Research Site

Greater Sudbury, Ontario, P3E 5J1, Canada
Research Site

Hamilton, Ontario, L8V 5C2, Canada
Research Site

Newmarket, Ontario, L3Y 2P9, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Moscow, 105077, Russia
Research Site

Moscow, 125367, Russia
Research Site

Novosibirsk, 630108, Russia
Research Site

Omsk, 644013, Russia
Research Site

Saint Petersburg, 194354, Russia
Research Site

Saint Petersburg, 195271, Russia
Research Site

Saint Petersburg, 199178, Russia
Research Site

Incheon, 21565, South Korea
Research Site

Seoul, 02841, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08036, Spain
Research Site

Madrid, 08035, Spain
Research Site

Madrid, 28041, Spain
Research Site

Málaga, 29010, Spain
Research Site

Santiago de Compostela, 15706, Spain
Research Site

Kaohsiung City, 807, Taiwan
Research Site

Kaohsiung City, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 104, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan City, 333, Taiwan
Research Site

Hanoi, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.